Diphtheria-tetanus-pertussis vaccine(Finlay Institute)(Diphtheria-tetanus-pertussis vaccine(Finlay Institute))

概要

基本信息

药物类型

联合疫苗、预防性疫苗、类毒素疫苗

别名-

靶点-

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病其他疾病

在研适应症

白喉破伤风百日咳

非在研适应症-

原研机构

Finlay Institute of Cuba

在研机构

Finlay Institute of Cuba

非在研机构-

最高研发阶段批准上市

首次获批日期

古巴 (2005-07-01),

白喉破伤风百日咳

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Diphtheria-tetanus-pertussis vaccine(Finlay Institute) 相关的临床试验

ACTRN12615001262594 / Completed临床4期IIT

A non-randomised cohort study to evaluate immunogenicity and reactogenicity of adult formulation diphtheria-tetanus-pertussis vaccine in healthy adult healthcare workers and researchers working with children: a comparison of those who have previously received a booster and those who are previously unvaccinated

开始日期2015-12-14

申办/合作机构

Telethon Kids Institute

JPRN-UMIN000021495 / Completed

Effect and safety of Diphteria-Pertussis-Tetanus vaccine among healthcare workers - Effect and safety of DTaP among healthcare workers

开始日期2015-03-02

申办/合作机构

Yokohama City University Medical Center

IRCT2013070713889N1 / Completed临床1期IIT

The comparison of injection order of the Diphtheria-Pertussis-Tetanus vaccine and Hepatitis B vaccine on pain response in infants

开始日期2012-12-21

申办/合作机构-

100 项与 Diphtheria-tetanus-pertussis vaccine(Finlay Institute) 相关的临床结果

登录后查看更多信息

100 项与 Diphtheria-tetanus-pertussis vaccine(Finlay Institute) 相关的转化医学

登录后查看更多信息

100 项与 Diphtheria-tetanus-pertussis vaccine(Finlay Institute) 相关的专利（医药）

登录后查看更多信息

753

项与 Diphtheria-tetanus-pertussis vaccine(Finlay Institute) 相关的文献（医药）

2024-12-01·Vaccine

Vaccine coverage and timeliness among children of adolescent mothers: A community-based study in the Eastern Cape, South Africa

Article

作者: Toska, Elona ; Weiss, Helen A ; Cluver, Lucie ; Doyle, Aoife M. ; Collins, Courteney ; Doyle, Aoife M ; Amponsah-Dacosta, Edina ; Wittesaele, Camille ; Weiss, Helen A.

BACKGROUNDChildren born to adolescent mothers are more vulnerable to infant mortality and morbidity than those born to adult mothers. HIV-exposed children have lower antibody protection against vaccine-preventable diseases at birth compared to unexposed children. In South Africa, 17 % of adolescent girls aged 15-19 years are mothers, yet vaccination coverage and timeliness among their children is underreported.METHODSThis study estimated age-appropriate vaccination coverage and timeliness among children (n = 1080) of adolescent mothers (n = 1015) in the Eastern Cape, South Africa. Mother-child dyads were recruited through healthcare and community-based sampling strategies. Vaccination data were abstracted from 1013 home-based child health records (2017-2019). Coverage is reported for Diphtheria-Tetanus-Pertussis 3rd dose (DTP3), under-1 vaccination among children over 12 months (n = 613) and measles 2nd dose (MCV2) among children over 24 months (n = 382) using proportions with 95 % confidence intervals (95 %CI). Timeliness is defined as receiving each vaccination within 4 weeks of recommended age. Findings are disaggregated by maternal HIV-status.RESULTSOverall, 27.3 % of adolescent mothers were living with HIV. Coverage of DTP3 was 85.6 % (95 %CI: 82.6-88.3 %), under-1 coverage was 53.2 % (95 %CI: 49.1-57.2 %), and MCV2 coverage was 62.3 % (95 %CI: 57.2-67.2 %). Vaccination coverage was lower among children of adolescent mothers living with HIV (AMLHIV) than unexposed children (DTP3 80.3 % vs 88.2 % p-value: 0.01; under-1 46.5 % vs 56.4 % p-value: 0.02; MCV2 55.4 % vs 67.1 % p-value: 0.02). Timeliness of vaccinations declined over time from 98.0 % at birth, 70.7 % at 14 weeks, 71.9 % at 9 months and 37.3 % at 18 months.CONCLUSIONVaccination coverage among children of adolescent mothers in the Eastern Cape are below national targets. Children of AMLHIV had lower coverage than HIV-unexposed children. Further research is needed to identify risk factors associated with incomplete and delayed vaccinations among this group, particularly among HIV-exposed children. Enhanced vaccination campaigns may be required for children of adolescent mothers.

2024-11-01·Allergy and Asthma Proceedings

A case of a rash after tetanus-diphtheria-pertussis and meningococcal vaccination

Article

作者: Acevedo, Joanne ; Kelly, Brent ; Adame, Fiona ; Salazar, Leonardo ; Covington, Cleavon

We present a case of a 12-year-old healthy girl who presented with acute onset of dry, hyperpigmented, and raised pruritic rash. The lesions initially presented on her thighs then progressed to the trunk and arms hours after receiving the tetanus-diphtheria-pertussis (Tdap) and meningococcal vaccine. After a poor response to medium potency topical steroids, a biopsy specimen was taken, which led to our diagnosis. Current literature reports this condition occurring after Tdap; measles, mumps, and rubella; and COVID-19 vaccinations; but, to our knowledge, not after meningitis vaccines. The role that vaccines play in the pathophysiology remains unclear. This condition may get mistaken for an allergic reaction and lead to vaccine avoidance.

2024-10-01·Vaccine

Estimation of the poliovirus type 2 immunity gap in South Africa

Article

作者: Mabhena, Nicoletta ; Molema, Koko ; van Schalkwyk, Cari ; von Gottberg, Anne ; Maseti, Elizabeth ; Brown, Lauren ; Prabdial-Sing, Nishi ; Botha, Sonia ; Sereo, Tumelo ; Bingham, Jeremy ; Mthombothi, Zinhle ; Schönfeldt, Marione ; Kamupira, Mercy ; McCarthy, Kerrigan ; Pulliam, Juliet

In the context of polio eradication efforts, accurate assessment of vaccination programme effectiveness is essential to public health planning and decision making. Such assessments are often based on zero-dose children, estimated using the number of children who did not receive the first dose of the Diphtheria-Tetanus-Pertussis containing vaccine as a proxy. Our study introduces a novel approach to directly estimate the number of children susceptible to poliovirus type 2 (PV2) and uses this approach to provide district-level estimates for South Africa of susceptible children born between 2017 and 2022. We used district-level data on annual doses of inactivated poliovirus vaccine (IPV) administered, live births, and population sizes, from 2017 through 2022. We imputed missing vaccination data, implemented flexible assumptions regarding dose distribution in the eligible population, and used estimated efficacy values for one, two, three, and four doses of IPV, to compute the number of susceptible and immune children by birth year. We validated our approach by comparing an intermediary output with zero-dose children (ZDC) estimated using data reported by WHO/UNICEF Estimates of National Immunization Coverage (WUENIC). Our results indicate high heterogeneity in susceptibility to PV2 across South Africa's 52 districts as of the end of 2022. In children under 5 years, PV2 susceptibility ranged from approximately 30 % in districts including Xhariep (31.9 %), Ekurhuleni (30.1 %), and Central Karoo (29.8 %), to less than 4 % in Sarah Baartman (1.9 %), Buffalo City (2.1 %), and eThekwini (3.2 %). Our susceptibility estimates were consistently higher than ZDC over the timeframe. We estimated that ZDC decreased nationally from 155,168 (152,737-158,523) in 2017 to 108,593 in 2021, and increased to 127,102 in 2022, a trend consistent with ZDC derived from data reported by WUENIC. While our approach provides a more comprehensive profile of PV2 susceptibility, our susceptibility and ZDC estimates generally agree in the ranking of districts according to risk.

100 项与 Diphtheria-tetanus-pertussis vaccine(Finlay Institute) 相关的药物交易

登录后查看更多信息